Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

U.S. Navy to investigate Oxygen Biotherapeutics' Oxycyte wound therapy

Oct. 8, 2012

Brimonidine improves erythema in patients with rosacea

Oct. 5, 2012

Adalimumab evaluated as a treatment for hidradenitis suppurativa in phase II trial

Oct. 5, 2012

PAC-14028 evaluated as a treatment for pruritus

Oct. 3, 2012

EMA recommends approval of ingenol mebutate for actinic keratosis

Sep. 28, 2012

RXi Pharmaceuticals completes dosing in first phase I trial of RXI-109

Sep. 27, 2012

EMA committee recommends approval of enzyme-based debriding agent for burn care

Sep. 26, 2012

Herb-based lotion relieves symptoms of atopic dermatitis

Sep. 26, 2012

Healthpoint Biotherapeutics begins phase III trial for venous leg ulcers

Sep. 13, 2012

Patient dosing begins in phase I/II trial of Pergamum's therapeutic peptide for hard-to-heal wounds

Sep. 12, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...